---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-004946"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2024-01-19T23:59:59+00:00"
generated_at: "2026-06-06T21:28:21.211460+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Allarity enters $440K convertible note with 3i, LP; Series A conversion price cut to $0.4476

## Summary
- Issued $440K principal senior convertible note to 3i, LP at $400K purchase price (10% OID), due Jan 18, 2025, 8% interest.
- Conversion price set at $0.4476 per share; Purchaser limited to 4.99% beneficial ownership cap.
- Second closing of $440K note at same terms may be required by company; potential additional $600K notes.
- Series A Preferred Stock conversion price amended from $1.00 to $0.4476 via Fifth Amendment.
- Proceeds used for accounts payable and working capital; negative covenants restrict further debt over $250K.

## SEC filing metadata
- accession: 0001213900-24-004946
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2024-01-19T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390024004946/0001213900-24-004946-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390024004946/ea191856-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-004946
- JSON: https://secwatch.observer/filing/0001213900-24-004946.json
- Plain text: https://secwatch.observer/filing/0001213900-24-004946.txt

## Key facts
- Debt Financings
  Allarity Therapeutics, Inc. incurred convertible notes of $440,000 with 3i, LP at 8% per annum maturing January 18, 2025.
  - Instrument: convertible notes
  - Principal: $440,000
  - Counterparty: 3i, LP
  - Rate: 8% per annum
  - Maturity: January 18, 2025
  - Event: incurrence
  source text: we issued and sold to the Purchaser a senior convertible promissory note in an aggregate principal amount of $440,000 (the “Principal Amount”) due on January 18, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390024004946/0001213900-24-004946-index.htm
- Material Agreements
  Allarity Therapeutics, Inc. entered into Securities Purchase Agreement with 3i, LP valued at $440,000 (effective 2024-01-18).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: 3i, LP
  - Value: $440,000
  - Effective: 2024-01-18
  source text: On January 18, 2024 (the “First Closing Date”), Allarity Therapeutics, Inc., a Delaware corporation (“we,” “our,” or the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with 3i, LP, a Delaware limited partnership (the “Purchaser”), pursuant to which we issued and sold to the Purchaser a senior convertible promissory note in an aggregate principal amount of $440,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390024004946/0001213900-24-004946-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.